OBJECTIVE: Generalized anxiety disorder (GAD) is a prevalent psychiatric condition in older adults with deleterious effects on health and cognition. Although selective serotonin reuptake inhibitor (SSRI) medications have some efficacy as acute treatments for geriatric GAD, incomplete response is the most common outcome of monotherapy. We therefore developed a novel sequential treatment strategy, using personalized, modular cognitive-behavioral therapy (mCBT) to augment SSRI medication. METHOD: In an open label pilot study (N = 10), subjects received a sequenced trial of 12 weeks of escitalopram followed by 16 weeks of escitalopram augmented with mCBT. We also examined the maintenance effects of mCBT over a 28-week follow-up period following drug discontinuation and termination of psychotherapy. RESULTS: Results suggest that (1) adding mCBT to escitalopram significantly reduced anxiety symptoms and pathological worry, resulting in full remission for most patients and (2) some patients maintained response after all treatments were withdrawn. CONCLUSION: Findings suggest that mCBT may be an effective augmentation strategy when added to SSRI medication and provide limited support for the long-term benefit of mCBT after discontinuation of pharmacotherapy.
OBJECTIVE: Generalized anxiety disorder (GAD) is a prevalent psychiatric condition in older adults with deleterious effects on health and cognition. Although selective serotonin reuptake inhibitor (SSRI) medications have some efficacy as acute treatments for geriatric GAD, incomplete response is the most common outcome of monotherapy. We therefore developed a novel sequential treatment strategy, using personalized, modular cognitive-behavioral therapy (mCBT) to augment SSRI medication. METHOD: In an open label pilot study (N = 10), subjects received a sequenced trial of 12 weeks of escitalopram followed by 16 weeks of escitalopram augmented with mCBT. We also examined the maintenance effects of mCBT over a 28-week follow-up period following drug discontinuation and termination of psychotherapy. RESULTS: Results suggest that (1) adding mCBT to escitalopram significantly reduced anxiety symptoms and pathological worry, resulting in full remission for most patients and (2) some patients maintained response after all treatments were withdrawn. CONCLUSION: Findings suggest that mCBT may be an effective augmentation strategy when added to SSRI medication and provide limited support for the long-term benefit of mCBT after discontinuation of pharmacotherapy.
Authors: M D Miller; C F Paradis; P R Houck; S Mazumdar; J A Stack; A H Rifai; B Mulsant; C F Reynolds Journal: Psychiatry Res Date: 1992-03 Impact factor: 3.222
Authors: Jürgen Unützer; Wayne Katon; Christopher M Callahan; John W Williams; Enid Hunkeler; Linda Harpole; Marc Hoffing; Richard D Della Penna; Polly Hitchcock Noël; Elizabeth H B Lin; Patricia A Areán; Mark T Hegel; Lingqi Tang; Thomas R Belin; Sabine Oishi; Christopher Langston Journal: JAMA Date: 2002-12-11 Impact factor: 56.272
Authors: S Paterniti; A Alpérovitch; P Ducimetière; M J Dealberto; J P Lépine; J C Bisserbe Journal: Psychosom Med Date: 1999 Jan-Feb Impact factor: 4.312
Authors: Josien Schuurmans; Hannie Comijs; Paul M G Emmelkamp; Ingrid J C Weijnen; Marcel van den Hout; Richard van Dyck Journal: Int Psychogeriatr Date: 2009-12 Impact factor: 3.878
Authors: Eric J Lenze; Bruce L Rollman; M Katherine Shear; Mary Amanda Dew; Bruce G Pollock; Caroline Ciliberti; Michelle Costantino; Sara Snyder; Peichang Shi; Edward Spitznagel; Carmen Andreescu; Meryl A Butters; Charles F Reynolds Journal: JAMA Date: 2009-01-21 Impact factor: 56.272
Authors: Carmen Andreescu; James J Gross; Eric Lenze; Kathryn Dunfee Edelman; Sara Snyder; Costin Tanase; Howard Aizenstein Journal: Depress Anxiety Date: 2011-03 Impact factor: 6.505